Cargando…

Drugging the epigenome in the age of precision medicine

BACKGROUND: Modulating the epigenome has long been considered a potential opportunity for therapeutic intervention in numerous disease areas with several approved therapies marketed, primarily for cancer. Despite the overall promise of early approaches, however, these drugs have been plagued by poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Feehley, Taylor, O’Donnell, Charles W., Mendlein, John, Karande, Mahesh, McCauley, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832256/
https://www.ncbi.nlm.nih.gov/pubmed/36631803
http://dx.doi.org/10.1186/s13148-022-01419-z
_version_ 1784868020341964800
author Feehley, Taylor
O’Donnell, Charles W.
Mendlein, John
Karande, Mahesh
McCauley, Thomas
author_facet Feehley, Taylor
O’Donnell, Charles W.
Mendlein, John
Karande, Mahesh
McCauley, Thomas
author_sort Feehley, Taylor
collection PubMed
description BACKGROUND: Modulating the epigenome has long been considered a potential opportunity for therapeutic intervention in numerous disease areas with several approved therapies marketed, primarily for cancer. Despite the overall promise of early approaches, however, these drugs have been plagued by poor pharmacokinetic and safety/tolerability profiles due in large part to off-target effects and a lack of specificity. RESULTS: Recently, there has been marked progress in the field on a new generation of epigenomic therapies which address these challenges directly by targeting defined loci with highly precise, durable, and tunable approaches. Here, we review the promise and pitfalls of epigenetic drug development to date and provide an outlook on recent advances and their promise for future therapeutic applications. CONCLUSIONS: Novel therapeutic modalities leveraging epigenetics and epigenomics with increased precision are well positioned to advance the field and treat patients across disease areas in the coming years.
format Online
Article
Text
id pubmed-9832256
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98322562023-01-11 Drugging the epigenome in the age of precision medicine Feehley, Taylor O’Donnell, Charles W. Mendlein, John Karande, Mahesh McCauley, Thomas Clin Epigenetics Review BACKGROUND: Modulating the epigenome has long been considered a potential opportunity for therapeutic intervention in numerous disease areas with several approved therapies marketed, primarily for cancer. Despite the overall promise of early approaches, however, these drugs have been plagued by poor pharmacokinetic and safety/tolerability profiles due in large part to off-target effects and a lack of specificity. RESULTS: Recently, there has been marked progress in the field on a new generation of epigenomic therapies which address these challenges directly by targeting defined loci with highly precise, durable, and tunable approaches. Here, we review the promise and pitfalls of epigenetic drug development to date and provide an outlook on recent advances and their promise for future therapeutic applications. CONCLUSIONS: Novel therapeutic modalities leveraging epigenetics and epigenomics with increased precision are well positioned to advance the field and treat patients across disease areas in the coming years. BioMed Central 2023-01-11 /pmc/articles/PMC9832256/ /pubmed/36631803 http://dx.doi.org/10.1186/s13148-022-01419-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Feehley, Taylor
O’Donnell, Charles W.
Mendlein, John
Karande, Mahesh
McCauley, Thomas
Drugging the epigenome in the age of precision medicine
title Drugging the epigenome in the age of precision medicine
title_full Drugging the epigenome in the age of precision medicine
title_fullStr Drugging the epigenome in the age of precision medicine
title_full_unstemmed Drugging the epigenome in the age of precision medicine
title_short Drugging the epigenome in the age of precision medicine
title_sort drugging the epigenome in the age of precision medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832256/
https://www.ncbi.nlm.nih.gov/pubmed/36631803
http://dx.doi.org/10.1186/s13148-022-01419-z
work_keys_str_mv AT feehleytaylor druggingtheepigenomeintheageofprecisionmedicine
AT odonnellcharlesw druggingtheepigenomeintheageofprecisionmedicine
AT mendleinjohn druggingtheepigenomeintheageofprecisionmedicine
AT karandemahesh druggingtheepigenomeintheageofprecisionmedicine
AT mccauleythomas druggingtheepigenomeintheageofprecisionmedicine